On July 20, 2020, Scott Braunstein, M.D. notified Protara Therapeutics, Inc. of his resignation from the Company’s Board of Directors (the “Board”), effective immediately. Dr. Braunstein’s resignation is not the result of any disagreement with the Company. Dr. Braunstein served on the Audit Committee of the Board (the “Audit Committee”) prior to his resignation from the Board. Effective August 3, 2020, Julio Casoy, M.D. will no longer be employed by the Company as Chief Medical Officer. On July 23, 2020, the Board appointed Barry Flannelly, Pharm.D, MBA as a Class III director to fill the vacancy created by Dr. Braunstein’s resignation, to serve in such capacity until the Company’s 2023 annual meeting of stockholders. Dr. Flannelly will be entitled to receive compensation for his service as a director of the Company in accordance with the Company’s Amended and Restated Non-Employee Director Compensation Policy.